家族性脑海绵状血管瘤首次症状性出血或癫痫的终生风险:多中心患者数据分析
该国际多中心回顾性队列纳入16个三级中心及1个患者倡导组织的1592例家族性脑海绵状血管瘤(FCM)患者,中位随访42年。首次症状性出血(SH)终生风险约80%,首次癫痫发作约45%,事件率在20岁后保持恒定。CCM3变异患者出血病程较CCM1更侵袭性(HR 1.799,95%CI 1.008-3.208),SH和癫痫独立关联末次随访时更差mRS。
要点
- FCM患者首次SH终生风险约80%,首次癫痫发作终生风险约45%。
- 20岁后SH和癫痫事件率保持恒定,累积终生风险高。
- CCM3变异出血病程较CCM1更侵袭性,HR 1.799(95%CI 1.008-3.208)。
核心结论
- FCM患者首次SH和癫痫的终生风险高,事件率随时间稳定,CCM3变异与更侵袭性出血病程相关。
研究设计与样本
- 国际多中心回顾性队列研究,纳入16个三级转诊中心和1个患者倡导组织的数据,共1592例确诊或疑似FCM患者,平均年龄37.6岁(SD 17.1),55.7%女性,中位随访42年(IQR 27-55),总计64146人年。
主要发现
- 869例(54.6%)确诊FCM,775例(48.7%)至少经历1次出血,447例(28.1%)至少经历1次癫痫发作。
- 首次SH终生风险约80%,事件率在20岁后保持恒定;首次癫痫发作终生风险约45%。
- 47.7%患者接受基因检测,识别CCM1(31.0%)、CCM2(4.8%)、CCM3(1.9%)变异。
- CCM3变异患者出血病程较CCM1更侵袭性(HR 1.799,95%CI 1.008-3.208)。
- SH和癫痫独立关联末次随访时更差mRS功能结局。
临床怎么用
- 对FCM患者应告知高终生SH和癫痫风险,尤其CCM3变异者需更密切监测。
- SH和癫痫与更差功能结局独立相关,临床管理需关注功能保护。
局限性
- 非人群基础设计,三级中心选择偏倚,回顾性数据收集,各中心数据提取存在变异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Familial cavernous malformations (FCMs) are vascular lesions that pose a lifelong risk of symptomatic hemorrhage (SH) and seizures, yet their natural history remains unclear. This study aims to determine the cumulative lifetime risk of a first SH and/or seizure and assess whether genetic variations influence these risks. METHODS: This international, multicenter retrospective cohort study included data from 16 tertiary referral centers and 1 patient advocacy group. Eligible patients had confirmed or suspected FCM, available magnetic resonance imaging (MRI) data, documented baseline clinical features, and longitudinal follow-up (FU). Functional outcomes were assessed using the modified Rankin Scale (mRS) at last FU. Direct adjusted survival curves and mixed-effects Cox regression analyses were performed to estimate cumulative lifetime risk. The association between genetic variations and SH/seizure rates was evaluated, and mixed-effects logistic regression assessed the effect of SH/seizures on mRS outcomes. RESULTS: A total of 1,592 patients with FCM were included, with a mean age of 37.6 years (SD 17.1) and 55.7% female. The median FU was 42 years (IQR: 27-55), totaling 64,146 person-years. Of these, 869 (54.6%) had confirmed FCM, 775 (48.7%) experienced at least 1 hemorrhage, and 447 (28.1%) had at least 1 seizure. Genetic testing was performed in 47.7%, identifying CCM1 (31.0%), CCM2 (4.8%), and CCM3 (1.9%) variations. The lifetime risk of a first SH was ∼80%, with an event rate that remained constant beyond age 20. The lifetime risk of a first seizure was ∼45%. Patients with CCM3 variations exhibited a more aggressive hemorrhagic course than those with CCM1 (hazard ratio 1.799, 95% CI 1.008-3.208). SH and seizures were independently associated with worse mRS outcomes at last FU. DISCUSSION: The event rate of SH and seizures remained stable over time, leading to high cumulative lifetime risks. Patients with CCM3 variations exhibited a more aggressive disease course. Limitations include the non-population-based design, selection bias from tertiary centers, retrospective data collection, and variability in data extraction across centers. However, this study represents the largest international FCM cohort to date, improving the precision of risk estimates and providing valuable insights into disease progression.
引用
- Dammann P, Santos AN, Mavarani L, et al. Lifetime Risk of First Symptomatic ICH or Seizure in Familial Cerebral Cavernous Malformations: A Multicenter Patient Data Analysis. Neurology. 2025. PMID: 40638881. doi:10.1212/WNL.0000000000213798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。